Valeant Pharma: Street Not Pleased With Future Financing Plans

by Joel Elconin, Benzinga Staff Writer

September 28, 2017 11:34 AM | 1 min read | Make a Comment

Valeant Pharmaceuticals Intl IncVRX

shares are trading lower by 70 cents at $13.70 in Thursday's session. Before the open, the company provided an update on their Canadian regulatory filing regarding future financing plans. At this time, the update is having a negative impact on the issue.

After a slightly lower open, it could regain Wednesday's closing price of $14.39, only reaching $14.32 before continuing its move lower. The follow-through decline has taken the issue to $13.55 and is not far off that low.

If the decline continues, the daily support level comes in at its Sept. 8 low of $13.33.

Market News and Data brought to you by Benzinga APIs

Posted In: Biotech Technicals Intraday Update Movers Trading Ideas General

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!